Goldfinch Bio, a U.S.-basedα↕, clinical stage biotechnology company focuseσ≈ d on discovering and develop'↔ing precision medicines for the treatm™αλent of kidney diseases, today announced it ♠₽≤ entered into a license agreement with T↓±akeda Pharmaceutical ←¶€Company Limited (“Takeda”) for worldwid&¶e rights to a preclinical, per₹₩φipherally-restricted cannabinoid rσ♣$eceptor 1 (CB1) monoclonal antibody. Goldfi✔'©nch Bio will assume all develop↕‌ment and commercialization responsibilit♦↕ies for the treatment of rare and metabolic kid×φ↕ney diseases worldwide<₹≤♣. However, the agreement grant£≥₽s Takeda the option, prior to the αγ✔Ωinitiation of pivotal studies, to request Go​≈ldfinch Bio negotiate with Takeda for sub-l♣♣icensing of Japanese rights to£β≠♦ Takeda. Financial terms of the♥δ  agreement were not disclose®★γd. Goldfinch Bio plans to file an investi↔‍gational new drug (IND) application for this ≠​σ>CB1 inhibitor, re-named GFB-024, in t∏•he second half of 2020.“In r'±¶ecent years, our understanding of the role of CB1↓✘≥< signaling in exacerbating progressive kidney♣≥∏± diseases has grown substantially. In th≤εis context, a monoclonal antibody directed↕®± toward the CB1 receptor is potent★±ially well-suited to elicit the >λbeneficial pharmacology associate ♦♠d with the peripheral inhibition of the CB1 rec'§™ eptor,” said Anthony Johnson, M.D., President and≥γ Chief Executive Officer o✘♥"f Goldfinch Bio. “Goldfinch Bio ¶₩$will deploy its biology platform and Kidn✔γ×ey Genome AtlasTM to deπ&≈♣velop this therapeutic agent inδ¥δ subsets of patients with kidney diseases€±® most likely to preferentiall£↕π≤y respond to CB1 inhibiti₹✘₽πon. With GFB-887, our TRPC5 inhibitor fo±✘r FSGS, in Phase 1 clinical d<£ ©evelopment, this periφ•§↑pheral CB1 inhibitor will be ♠σ♥ the second clinic-ready program≤"↑ in Goldfinch Bio’s pipeline. We lookσ→→≥ forward to collaborating with Takeda≥★Ω₹ on this program.”“Goldfinch Bio is ideally sui'☆ted to advance development←φ↑₹ of this program,” said Dan Curran, ↕♠←M.D., SVP and Head, Rare Diseases Therapeuticπ✘₹ Area Unit, Takeda. “The app₽↓lication of its precision medic₽ ​ine approach, from candidate tarβ÷$get validation throu✘‍¶gh to identification of potential treat & •ment-relevant subgroups,↔♠γ‌ is unique in the development of chronic ÷®metabolic kidney disease treatments.”Preclinic₽∞δ≠al data support the inhibition  εσof CB1 signaling as a nov☆©♠el treatment of Diabetic  ≠"Nephropathy (DN) and ≠ obesity-related glomerulopathies (OR‍≤®✔G), given the potential metabolic benefi §←≠ts and direct effects on the kidney to pre§≥↑vent fibrosis and preserve kidney function.¥♥∞ DN develops in 30 to 40 percent of patienπ®'εts who have diabetes and is a leading cause of moφαrbidity, mortality and end-stage kidney disease  γin the United States a®★nd worldwide. ORG is a •εrare kidney disorder characterized× ® by significant proteinuria and progressive rena δ™l dysfunction. Although bot&±β&h DN and ORG are increasing in prevalence i&§$★n parallel with the obesity epidemic ₽×, well-established disease modifying ∞ ε£therapies are lacking. Goldfinch Bio plans to ini€↓Ωtiate a phase 1 study for GFB-024 in 2H↓∏ 2020.information source:pharma focus AsiaT' β↓he original link:https://www.® pharmafocusasia.com/news/÷∏goldfinch-bio-announces-licensing-agreement-wit<↕h-takeda-for-cb1-monoclonal-antibo∑ ★≠dy-for-the-treatment-of-rare-and-metab'₹olic-kidney-diseases2019 Asia-​♣≈βpacific pharma IP Leader Summit: http://en.zense€♦↕πegroup.com/p/404716/ w±<∏ill be held in Beijing&nλ₽→bsp; on November 14-15, and will at∞σ<δtract more than 500 industry experts from domes∏α∏tic and foreign pharmaceutical companies, biotec•☆ ∞hnology companies, governments, associatio α<ns, law firms, intellectual property agents and o∑♥ε✔ther companies to attend.Official registration≈‍ and consultation channels:Contact：AnnPhone: 021-©‌₩↔65650305Email：Marketing@zenseegroup.comhπβttp://en.zenseegroup.com/p/51093 €✔ 4/